Key Takeaways:
Nuvectis Pharma secured worldwide rights to NXP100, a once-daily oral PNH therapy that beat the infused standard of care by a 7-to-1 margin in Phase 3.
The deal transforms Nuvectis from a single mid-stage oncology company into a rare-disease player with a late-stage asset already entering regulatory review, the company said in its June announcement.
In a randomized Phase 3 trial against eculizumab, the infused standard of care for paroxysmal nocturnal hemoglobinuria for nearly two decades, 59.5 percent of patients on NXP100 reached a normal hemoglobin level without requiring a blood transfusion. Only 8.3 percent of patients on eculizumab achieved that endpoint. NXP100 targets Factor B, a protein upstream in the complement cascade, shutting down the immune attack on red blood cells with a single daily pill taken at home.
Two marketing authorization applications for NXP100 are under review with China's National Medical Products Administration, with first approval decisions expected within the next six to twelve months. Nuvectis licensed worldwide rights outside China to NXP100 and a second oncology asset, NXP200, from Haisco Pharmaceutical Group for $40 million upfront and up to $1.42 billion in milestone payments.
The global PNH treatment market is projected to grow to approximately $9.8 billion by 2030 from $5.75 billion in 2024, according to Grand View Research. Novartis's Fabhalta, the first approved oral Factor B inhibitor and NXP100's closest competitor, posted $169 million in first-quarter 2026 sales, more than double the prior-year period. AstraZeneca's Soliris franchise, the older infused therapy, saw sales fall 14 percent year over year in the same period.
The market has rewarded simpler-dosing profiles in 2026. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for roughly $10 billion in July for a once-daily oral acromegaly therapy. Jade Biosciences reached a valuation above $1.3 billion on Phase 1 data for a quarterly-dosed antibody, and TG Therapeutics climbed to an $8 billion-plus market cap partly on a self-administered version of its multiple sclerosis drug.
The NXP100 regulatory decision gives Nuvectis a concrete event within a year, layered on top of additional NXP900 oncology data expected this summer and NXP200 program readouts to follow. The company also completed a $100 million public offering of common stock in June, providing capital to advance the expanded pipeline.
This article is for informational purposes only and does not constitute investment advice.
